Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 3/20 | 0.34 |
| ▸ | GABRD | O14764 | 3/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.34 |
| ▸ | GABRE | P78334 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512484 | 0.83 | HDAC1 (0.32) | SYKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4039418 | 0.76 | CYP2C19 (0.57) | SYKCYP2C9CYP2C19NFKB1NFKB2 | |
| SCHEMBL15932872 | 0.76 | CYP1A2 (0.44) | SYKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2610396 | 0.75 | BACE1 (0.35) | SYKGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20399682 | 0.74 | JMJD6 (0.43) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 | |
| SCHEMBL4018903 | 0.74 | THRB (0.43) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 | |
| SCHEMBL29664441 | 0.74 | THRB (0.43) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 | |
| SCHEMBL30697102 | 0.74 | JMJD6 (0.43) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 | |
| SCHEMBL15968597 | 0.73 | CA12 (0.46) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 | |
| SCHEMBL7684716 | 0.72 | S1PR1 (0.49) | CYP2C9CYP2C19JMJD6GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200330477-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10463675-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3183247-B9 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3183247-B1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3183247-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | Pfizer Inc (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9663526-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.